PMC:7441788 / 17675-18682 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T108","span":{"begin":868,"end":871},"obj":"Body_part"},{"id":"T109","span":{"begin":902,"end":925},"obj":"Body_part"}],"attributes":[{"id":"A108","pred":"fma_id","subj":"T108","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma45661"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T8","span":{"begin":902,"end":925},"obj":"Body_part"},{"id":"T9","span":{"begin":908,"end":925},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T102","span":{"begin":296,"end":304},"obj":"Disease"}],"attributes":[{"id":"A102","pred":"mondo_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T180","span":{"begin":22,"end":27},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T181","span":{"begin":343,"end":344},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T226","span":{"begin":22,"end":27},"obj":"Chemical"},{"id":"T227","span":{"begin":61,"end":66},"obj":"Chemical"},{"id":"T228","span":{"begin":84,"end":89},"obj":"Chemical"},{"id":"T229","span":{"begin":361,"end":366},"obj":"Chemical"},{"id":"T230","span":{"begin":538,"end":547},"obj":"Chemical"}],"attributes":[{"id":"A226","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A227","pred":"chebi_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A228","pred":"chebi_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A229","pred":"chebi_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A230","pred":"chebi_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T9","span":{"begin":412,"end":424},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T10","span":{"begin":938,"end":960},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A9","pred":"meddra_id","subj":"T9","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062026"},{"id":"A10","pred":"meddra_id","subj":"T10","obj":"http://purl.bioontology.org/ontology/MEDDRA/10049413"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T136","span":{"begin":868,"end":871},"obj":"Chemical"}],"attributes":[{"id":"A136","pred":"chebi_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/CHEBI_33697"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T104","span":{"begin":296,"end":304},"obj":"Species"}],"attributes":[{"id":"A104","pred":"ncbi_taxonomy_id","subj":"T104","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T131","span":{"begin":0,"end":16},"obj":"Sentence"},{"id":"T132","span":{"begin":17,"end":98},"obj":"Sentence"},{"id":"T133","span":{"begin":99,"end":305},"obj":"Sentence"},{"id":"T134","span":{"begin":306,"end":334},"obj":"Sentence"},{"id":"T135","span":{"begin":335,"end":533},"obj":"Sentence"},{"id":"T136","span":{"begin":534,"end":717},"obj":"Sentence"},{"id":"T137","span":{"begin":718,"end":794},"obj":"Sentence"},{"id":"T138","span":{"begin":795,"end":1007},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T8","span":{"begin":902,"end":925},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"644","span":{"begin":265,"end":273},"obj":"Species"},{"id":"645","span":{"begin":607,"end":615},"obj":"Species"},{"id":"646","span":{"begin":785,"end":793},"obj":"Species"},{"id":"671","span":{"begin":57,"end":60},"obj":"Chemical"},{"id":"672","span":{"begin":99,"end":102},"obj":"Chemical"},{"id":"673","span":{"begin":205,"end":208},"obj":"Chemical"},{"id":"674","span":{"begin":560,"end":563},"obj":"Chemical"},{"id":"675","span":{"begin":654,"end":657},"obj":"Chemical"},{"id":"711","span":{"begin":296,"end":304},"obj":"Disease"}],"attributes":[{"id":"A644","pred":"pubann:denotes","subj":"644","obj":"Tax:9606"},{"id":"A674","pred":"pubann:denotes","subj":"674","obj":"MESH:D006886"},{"id":"A645","pred":"pubann:denotes","subj":"645","obj":"Tax:9606"},{"id":"A675","pred":"pubann:denotes","subj":"675","obj":"MESH:D006886"},{"id":"A672","pred":"pubann:denotes","subj":"672","obj":"MESH:D006886"},{"id":"A673","pred":"pubann:denotes","subj":"673","obj":"MESH:D006886"},{"id":"A671","pred":"pubann:denotes","subj":"671","obj":"MESH:D006886"},{"id":"A711","pred":"pubann:denotes","subj":"711","obj":"MESH:C000657245"},{"id":"A646","pred":"pubann:denotes","subj":"646","obj":"Tax:9606"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T118","span":{"begin":172,"end":179},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T119","span":{"begin":196,"end":203},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T120","span":{"begin":538,"end":547},"obj":"http://purl.obolibrary.org/obo/IDO_0000559"},{"id":"T121","span":{"begin":661,"end":668},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T107","span":{"begin":868,"end":871},"obj":"Body_part"},{"id":"T108","span":{"begin":902,"end":925},"obj":"Body_part"}],"attributes":[{"id":"A108","pred":"fma_id","subj":"T108","obj":"http://purl.org/sig/ont/fma/fma45661"},{"id":"A107","pred":"fma_id","subj":"T107","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T95","span":{"begin":296,"end":304},"obj":"Disease"}],"attributes":[{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T60","span":{"begin":984,"end":989},"obj":"http://purl.obolibrary.org/obo/GO_0071878"},{"id":"T61","span":{"begin":984,"end":989},"obj":"http://purl.obolibrary.org/obo/GO_0071877"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-PubTator","denotations":[{"id":"644","span":{"begin":265,"end":273},"obj":"Species"},{"id":"645","span":{"begin":607,"end":615},"obj":"Species"},{"id":"646","span":{"begin":785,"end":793},"obj":"Species"},{"id":"671","span":{"begin":57,"end":60},"obj":"Chemical"},{"id":"672","span":{"begin":99,"end":102},"obj":"Chemical"},{"id":"673","span":{"begin":205,"end":208},"obj":"Chemical"},{"id":"674","span":{"begin":560,"end":563},"obj":"Chemical"},{"id":"675","span":{"begin":654,"end":657},"obj":"Chemical"},{"id":"711","span":{"begin":296,"end":304},"obj":"Disease"}],"attributes":[{"id":"A644","pred":"tao:has_database_id","subj":"644","obj":"Tax:9606"},{"id":"A645","pred":"tao:has_database_id","subj":"645","obj":"Tax:9606"},{"id":"A646","pred":"tao:has_database_id","subj":"646","obj":"Tax:9606"},{"id":"A671","pred":"tao:has_database_id","subj":"671","obj":"MESH:D006886"},{"id":"A672","pred":"tao:has_database_id","subj":"672","obj":"MESH:D006886"},{"id":"A673","pred":"tao:has_database_id","subj":"673","obj":"MESH:D006886"},{"id":"A674","pred":"tao:has_database_id","subj":"674","obj":"MESH:D006886"},{"id":"A675","pred":"tao:has_database_id","subj":"675","obj":"MESH:D006886"},{"id":"A711","pred":"tao:has_database_id","subj":"711","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"LitCovid-sentences","denotations":[{"id":"T131","span":{"begin":0,"end":16},"obj":"Sentence"},{"id":"T132","span":{"begin":17,"end":98},"obj":"Sentence"},{"id":"T133","span":{"begin":99,"end":305},"obj":"Sentence"},{"id":"T134","span":{"begin":306,"end":334},"obj":"Sentence"},{"id":"T135","span":{"begin":335,"end":533},"obj":"Sentence"},{"id":"T136","span":{"begin":534,"end":717},"obj":"Sentence"},{"id":"T137","span":{"begin":718,"end":794},"obj":"Sentence"},{"id":"T138","span":{"begin":795,"end":1007},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}

{"project":"2_test","denotations":[{"id":"32496926-32409561-132195703","span":{"begin":12,"end":14},"obj":"32409561"}],"text":"Tang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. Randomized controlled study. Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. The trial terminated early due to the difficulty to recruit enough patients. Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results."}